She says the medications lower the odds of heart attack, stroke and cardiovascular death in patients with obesity, with or without diabetes.
Recap by typeshit. Post by @njeri.md on Instagram.
A physio fielding years of peptide questions says strong studies are lacking, while noting that a lack of evidence doesn't prove they fail.
Up to half of participants in the two trials of the experimental drug ended up with only mild sleep apnea, per the post.
Nippard puts the two approved drugs on top for supervised weight loss and holds retatrutide at B-tier until it is approved.
Bloomberg traces how Amgen used genetic data from Iceland to guide its obesity drug research.
One user says her period returned after two months on tirzepatide without medroxyprogesterone and asks others to compare.
A short take arguing that metabolic drugs are valid tools and that people who use them shouldn't feel they have to keep it quiet.
Loading…